Adoptive immunotherapy with allogeneic purified natural killer (NK) cell products might exert graft-versus-tumor alloreactivity with little risk of GVHD. In a prospective phase II study in two centers, we administered purified NK cell products to high-risk patients treated with haploidentical T-cell-depleted SCT. Sixteen patients received a total of 29 NK cell infusions on days þ 3, þ 40 and þ 100 after transplantation. Median doses (and ranges) of infused NK-and T-cells per product were 1.21 (0.3-3.8) Â 10 7 /kg and 0.03 (0.004-0.72) Â 10 5 /kg, respectively. With a median follow-up of 5.8 years 4/16 patients are alive. Cause of death was relapse in five, GVHD in three, graft failure in three, and transplant related neurotoxicity in one patient. Four patients developed acute GVHDXgrade II, all receiving a total of X0.5 Â 10 5 T cells/kg. Compared with historical controls, NK cell infusions had no apparent effect on the rates of graft failure or relapse. Adoptive transfer of allogeneic NK cells is safe and feasible, but further studies are needed to determine the optimal dose and timing of NK cell therapy. Moreover, NK cell activation/expansion may be required to attain clinical benefit, while careful consideration must be given to the number of T cells infused.
INTRODUCTION
Allogeneic hematopoietic SCT (HSCT) from an HLA-identical donor is curative for many patients with hematological malignancies. However, for patients lacking an HLA-identical donor and for those with progressive disease, the use of haploidentical family donors is increasingly considered to be a suitable alternative. 1, 2 In the traditional protocol pioneered by the Perugia group, 3 vigorous T-cell depletion and high numbers of CD34 þ cells are required to cross the HLA barrier, avoiding severe GVHD.
Adoptive immunotherapy using DLI is standard practice after HLA-matched allogeneic HSCT to treat patients with mixed chimerism or impending relapse. 4, 5 After haploidentical HSCT, unmodified DLI are given only cautiously because of the high risk of severe GVHD. 6 In contrast, natural killer (NK) cells may mediate antitumor activity without causing GVHD and therefore provide an attractive platform for immunotherapy after haploidentical HSCT. Although alloreactive NK cells are eventually produced by the graft itself, 7, 8 the NK cells that arise in the first weeks after CD34 þ selected haploidentical transplantation are mostly immature and hypofunctional. 9, 10 Purified donor-derived NK cells instead are mature and functional, and their infusion early after transplantation might overcome some of the problems associated with T-celldepleted haploidentical HSCT. 11 Adoptive immunotherapy with highly purified NK cells has been investigated by several groups showing the feasibility of NK cell application without severe side effects. [11] [12] [13] With regard to NK cell efficiency, a recent study 14 reported that NK cell infusion to 10 pediatric patients with AML in first CR led to a two-year EVS of 100%. Preliminary results appear encouraging, but crucial issues such as patient and donor selection, best timing for NK cell infusions, NK cell target dose, and possible gains by in vitro activation and expansion remain unresolved. As only about 10% of peripheral blood lymphocytes are NK cells, their stringent purification also poses a major technical challenge. So far these NK cell studies were performed in low-/middle-risk patients or in a non-transplant situation. Data on NK cell infusion post HSCT in patients with advanced stages of their disease are still lacking.
We here report on a phase II study including 16 patients with high-risk leukemia or multiply relapsed tumors in two centers receiving adoptive immunotherapy with highly purified NK cells at different time points after haploidentical HSCT to prevent graft failure and to add antitumor effects without causing GVHD.
PATIENTS AND METHODS

Study design
Following preliminary data from a pilot phase, 15, 16 the primary objectives were to collect, purify and administer NK cell DLIs (NK-DLIs) pre-emptively in recipients of haploidentical stem cell transplants in a two-center phase II study (center A: Basel, Switzerland; center B: Frankfurt am Main, Germany). Target cell doses were X1.0 Â 10 7 /kg CD56 þ /CD3 À NK cells, with o1.0 Â 10 5 /kg contaminating CD3 þ T cells to address feasibility and toxicity of the procedure. Secondary end points included a first view of the impact of NK cell immunotherapy on engraftment, relapse, and on immune reconstitution. Special consideration was given to the HLA constellation between donor and recipient, which may or may not encompass a favorable killer-cell Ig-like receptor (KIR) ligand mismatch. 7, 8 To investigate very early versus early NK applications, donors in center A had NK cells harvested on day þ 40 and NK-DLI were planned for days þ 40 and þ 100 after transplant. In center B, NK cells were harvested twice, before the transplant and on day þ 40 and NK-DLI was infused on days þ 3, þ 40 and þ 100 as shown in Figure 1 . Informed consent was obtained from the adult patients, or the children and their caretaker, respectively. The study was approved by the local ethical committees at both study sites and registered at http://clinicaltrials.gov (NCT01386619).
Defined study exclusion criteria prior to NK-DLI were graft failure or patients with persisting acute or chronic GVHD. Study discontinuation criteria were severe GVHD (X grade III) or other toxicities. Rates of acute GVHDXgrade II, graft rejection and survival were compared with two historical cohorts treated at both centers with haploidentical HSCT without NK-DLI.
Patients and conditioning regimen
Sixteen patients suffering from high-risk leukemia or highly malignant solid tumors were included in the protocol between 2004 and the end of 2005. The protocol allowed the inclusion of 15 patients in both centers. Overlapping inclusion of the last patient each in the two centers led to 16 patients being included. Characteristics of these patients are listed in Table 1 . All were children or young adults with high-risk malignancies. Seven patients (44%) had active disease at time of the transplant. Two patients had relapsed after prior allogeneic HSCT from an unrelated donor. Haploidentical donors were parents or siblings and all were fully haplotype mismatched. As parts of their SCT products, patients had received a median of 12.5 (7-30) Â 10 6 /kg BW CD34 þ cells and 0.09 (0-1.6) Â 10
Haploidentical HSCT was performed as per institutional protocol after myeloablative conditioning including ATG (center A) or OKT3 (center B), G-CSF-mobilized peripheral blood stem cells, a T-cell-depleted (target o1.0 Â 10 5 /kg CD3 þ ) graft with a high dose of CD34 þ cells (target X10 Â 10 6 /kg), post-transplant immunosuppression with OKT3 and a short course of cyclosporine in both centers. All grafts were T-cell depleted by CD34 þ selection, except for three patients in center B who received CD3/ CD19-depleted grafts instead. These patients received additional GVHD prophylaxis with mycophenolate mofetil. Chimerism after HSCT was monitored in cellular subsets using a PCR assay analyzing polymorphic short tandem repeats. 17 Purification of donor NK cells and quality control Mononuclear cells were collected from the stem cell donor by 10-15 L unstimulated leukapheresis. The two-step ex vivo purification procedure (CliniMACS cell selection system) included CD3 depletion followed by a CD56-positive selection. 16, 18, 19 At each step, cells were analyzed for percentage and viable absolute number of CD56 þ CD3 À , CD3 þ and by flow cytometry in single and dual platform approaches as described previously. 20, 21 In case of a contaminating T-cell dose of X1.0 and o2.0 Â 10 5 /kg, the processed NK product was split into two units. In both centers, all patients received the NK-DLI unit freshly isolated at day þ 40 post HSCT; the next unit at day þ 100 was always cryopreserved. To avoid a possible negative impact of G-CSF stimulation during stem cell harvesting, collection of the first NK-DLI in center B was performed pretransplant at day À 10. Therefore, the first NK infusions in center B at day þ 3 were with cryopreserved units, whereas in center A all first infusions were with freshly harvested units at day þ 40. NK-DLI administrations were performed as an outpatient procedure, with the exception of the day þ 3 infusion in center B. Cryopreserved NK cell units were thawed at the bedside and infused rapidly. Patients were monitored for immediate adverse reactions, GVHD, reconstitution of various lymphocyte sub-populations and infections. For quality control of the final NK cell product before NK-DLI, cytotoxic activity against K562 cells were performed as we described previously.
22,23
RESULTS
Feasibility of large-scale NK cell engineering and application
The primary goal of this study-to successfully engineer a NK cell DLI product containing410 7 /kg highly purified donor CD56 þ CD3 À cells from one unstimulated apheresis-could be reached in the majority of our patients (81%, 13/16). Median dose of all 29 applied NK-DLI was 1.21 (range 0.3-3.8) 10
7 /kg CD56 þ CD3 À cells. As shown previously, recipient weight is the limiting factor regarding the ability to generate NK cell products with a large NK cell dose per kg. protocol allowing up to 1 Â 10 5 /kg CD3 þ cells. All patients included in the study received a first NK cell dose, five patients did not receive a second dose (two because of GVHD, one because of graft failure, one because of early disease progression and one patient withdrew from the study). Only two patients received a third dose. As shown in Table 2 , NK cell yield was B50%. Differences between centers may be explained by an additional washing step in center B and by overnight storage of the apheresis product prior to NK purification. 19 Median NK cell cytotoxicity of the NK-DLI against the MHC class I-negative K562 cells in the effector:target ratios 1:1 and 10:1 was 30% and 75%, respectively. Rethawing of cryopreserved NK cells was associated with a median viability and recovery of 84% and 80%, respectively, as measured in the cell products of three patients.
Safety of NK-DLI
The transfusion of NK-DLI was well tolerated in the short term. There were no immediate reactions noted. Four patients went on to develop acute GVHDXgrade II: one in center A where NK-DLI were transfused on day þ 40 (GVHD grade IV, onset on day 67). Two patients developed early and one patient late acute GVHD in center B where NK-DLI were given on day þ 3, which precludes stringent assessment as to whether the GVHD was associated with the graft or with the day NK-DLI in these cases (GVHD of grades II, III, III on days 31, 33, 60, respectively). Of note, all four patients developing GVHDXgrade II received a cumulative CD3 þ T-cell dose of 40.5 Â 10 5 cells/kg. In two cases (one in center A and one in center B) these residual T cells originated mainly from the NK cell therapy, whereas in the other two cases the majority of T cells were administered as part of the CD3/CD19-depleted graft (1 Â 10 5 and 1.6 Â 10 5 CD3 þ T cells/kg BW, respectively). In three of these four patients (those with grades III/IV), GVHD was eventually fatal. Cumulative NK-and T-cell contents of both the given stem cell graft and of all applied NK-DLIs, and their relation to the degree of acute GVHD are shown in Figure 2 . In ordinal regression, grade of acute GVHD was associated with cumulative dose of infused T cells (r 2 ¼ 0.75, Po0.001), but not with cumulative dose of infused NK cells (r 2 ¼ 0.02, P ¼ 0.59). Importantly, none of the patients receiving o0.5 Â 10 5 /kg total CD3 þ cells (stem cell graft and NK-DLI combined) developed any sign of GVHD4 grade I.
Of the two NK cell products that presumably directly caused acute GVHD, one was KIR ligand mismatched with the donor (Tand NK-cell content 0.53 Â 10 5 /kg and 2.47 Â 10 7 /kg, respectively), whereas the other was KIR ligand matched (T-and NK-cell content 0.72 Â 10 5 /kg and 3.4 Â 10 7 /kg, respectively). Two of the transplants leading to a GVHD4grade I were from maternal donors (of a total of seven maternal donor transplants), the remaining two from paternal donors (of a total of nine non-maternal donor transplants).
In a retrospective comparison with patients treated with haploidentical HSCT without NK-DLI (center A: n ¼ 27, center B, n ¼ 35), the rate of GVHDXgrade II was similar in our NK-DLI trial (25%) to the rate observed in center B employing CD3 þ /CD19 þ depletion for T-cell removal (GVHDXgrade II in 24% of patients; n ¼ 25), whereas GVHDXgrade II occurred in only 3% of the patients (n ¼ 37) in center A and B, where T-cell depletion by CD34 þ selection was used exclusively.
Efficacy of NK-DLI Median follow-up in surviving patients is 5.8 (5.3-6.8) years. In spite of pre-emptive NK-DLI, three patients experienced graft failure (fatal in all three). The rate of graft rejection in this trial (19%) was not decreased when compared with that of the historical cohorts treated without NK-DLI (center A: 11%; center B: 4% for CD3/CD19-depleted grafts and 10% for CD34 selected grafts, respectively). Seven patients relapsed with their original disease, of which six died. Relapses were in AML (4/8), Hodgkin's disease (1/2) and rhabdomyosarcoma (1/1), whereas of the patients with ALL only 1/4 relapsed. The presence or absence of a KIR ligand mismatch between donor and patient had no discernible effect on the risks of graft failure or relapse, although numbers analyzed were small and heterogeneous with regard to the diseases. Survival probabilities for the entire cohort were 44±12% at 1 year and 25±11% at 2 years and 5 years, as shown in Figure 3 . Compared with 5-year survival rates in the historical cohorts treated with haploidentical HSCT without NK-DLI (center A 26%, center B 43%), survival rates were not improved.
Immune reconstitution was successful in 13/16 patients. Reconstitution of lymphocyte subsets was comparably fast: at day 100 after transplantation, median CD8 and CD4 T-cell counts were 266 and 181 mL, respectively. Chimerism at day 100 was full donor type in 11/16 patients. Of the remaining five patients, two had already rejected the graft by that time; one patient with mixed chimerism later developed disease relapse; and two patients are alive and disease free with stable mixed chimerism.
Two patients in this trial proved interesting regarding potential effects of NK-DLI regarding efficacy of converting mixed chimerism: both presented with split chimerism early after Pre-emptive immunotherapy with NK-DLI M Stern et al transplantation (donor type on NK cells and granulocytes, host type on 490% of T cells). In both patients, NK cell infusions had no measurable effect on T-cell chimerism. Eventually (41 year after transplantation), mixed chimerism within the T-cell compartment developed in both patients and remained until the end of follow-up. In one other patient transplanted for a CBFb/MYH11-positive acute myeloid leukemia, the fusion transcript remained detectable at low levels after transplantation while the patient was in hematological remission. Despite administration of three NK-DLI products, the quantity of the fusion transcript slowly increased and the patient eventually progressed to hematological relapse.
DISCUSSION
Adoptive immunotherapy using NK cells has been previously suggested to improve donor chimerism in patients at a distance from transplant with decreasing proportions of donor cells in the peripheral blood. This phase II study was devised to analyze feasibility, safety and efficacy of pre-emptive adoptive immunotherapy in patients with high-risk malignancies after haploidentical HSCT. Data in 16 high-risk patients show that a NK cell dose of 1 Â 10 7 /kg CD56 þ CD3 À cells can be procured from one unstimulated leukapheresis in the majority (480%), but not in all patients. NK-DLI were T-cell depleted to avoid clinical GVHD. Despite this, in our study, 4/16 patients developed acute GVHD gradeXII, three of them receiving a very early NK-DLI at day þ 3 and one patient at day þ 40. Of note, all four patients received cumulative doses of 40.5 Â 10 5 CD3 þ T cells/kg BW (transplant and NK-DLI combined). Two patients received a high number of T cells in the CD3/CD19-depleted graft (X1 Â 10 5 CD3 þ T cells/kg BW), and two others received NK-DLI with a high residual T-cell count. Purification of all other NK cell products was efficient leading to a contaminating T-cell number of p0.2 Â 10 5 CD3 þ T cells/kg BW and no sign of severe GVHD. It is therefore improbable that GVHD is caused by NK cells, but is more likely due to T cells contaminating the NK cell or the stem cell product. The cumulative T-cell threshold of 0.5 Â 10 5 /kg found in this study correlated well with previous 'safe' T-cell doses defined in patients receiving haploidentical marrow transplantation for immunodeficiency or leukemia. 24, 25 The fact that T-cell doses above this threshold induced GVHD, even if given together with a more than 100-fold larger dose of NK cells, argues against a strong protective effect of human NK cells against GVHD, as has been demonstrated for the murine setting. 8 NK-DLI were given to protect from graft failure and relapse. Results in our heterogeneous patient group suffering from highrisk leukemias and tumors are not promising so far. We did not find rates of graft failure or relapse lower than those observed in historical controls treated with haploidentical HSCT without NK-DLI. We furthermore did not find any differences favoring NK-DLI in recipients KIR ligand mismatched with their respective donors as compared with KIR ligand-matched patients. Significantly, one patient with low-level minimal residual disease as measured by quantitative PCR relapsed despite infusion of three NK cell DLI products from a KIR ligand-mismatched donor. Furthermore, two patients with split chimerism could not be converted to donor chimerism by infusion of NK cells. These data raise the question whether the dose of NK cells administered in this study was sufficient to induce any clinical effect, or whether NK cells should rather be expanded (in vitro or in vivo) to achieve sufficient cell numbers.
Future development of NK-based adoptive immunotherapy will include better characterization of NK cell alloreactivity to maximally exploit the anti-leukemic effects. Furthermore, in vitro NK cell activation and expansion to obtain higher doses of possibly more effective cell populations need to be studied. 26, 27 Some single-center experiences showed a benefit of IL-2-stimulated NK cells compared with freshly isolated, resting NK cells with regard to the cytotoxicity against leukemic and tumor targets. 18, [28] [29] [30] [31] This was due to a strong upregulation of the activating receptors NKp30, NKp44, NKp46 and NKG2D during IL-2 stimulation. 18 Further investigations might improve on this by activation with additional cytokines like IL-15, IL-18 or IL-21. 28, [32] [33] [34] Nevertheless those strategies require close patient monitoring to investigate the influence of the respective cytokine on the cell sub-population in peripheral blood. Very recently, we could show that IL-2-stimulated NK-DLI but not unstimulated NK-DLI promote NK cell trafficking and changes in the distribution of leukocyte sub-populations in the peripheral blood. 35 Interestingly, stimulated NK-DLI led to a rapid loss of CD56(bright)CD16(dim) immune regulatory and CD56(dim)CD16( þ ) cytotoxic NK cells, monocytes, dendritic cells and eosinophils from patients' peripheral blood circulation 10 min after infusion. We could demonstrate that the reduction of NK cells was due to both, a decrease in patients' own CD69(2) NCR(low)CD62L( þ ) NK cells and to a diminishing of the transferred cells from the stimulated NK-DLI. After 24 h all cell counts recovered. In addition, we found that the transfer of stimulated NK-DLI led to significantly increased Years of follow-up Overall survival Figure 3 . Probability of overall survival after transplantation and NK-DLI treatment.
levels of various cytokines/chemokines (that is, IFN-c, IL-6, MIP-1b) in patients' peripheral blood. Those remained stable for at least 1 h, presumably leading to endothelial activation, leukocyte adhesion and extravasation. In contrast, unstimulated NK-DLI did not cause any of the observed effects. Although these differences seemed to have a major influence on the patients immune cells, the medium-and long-term cellular immune reconstitution post haploidentical SCT did not differ between patients receiving stimulated versus unstimulated NK-DLI or compared with patients without NK cell application. However, our patients groups were small and heterogeneous with regard to the underlying disease.
In our concomitant study we could demonstrate that high plasma levels of soluble MHC class I chain-related gene A (sMICA) in patients with tumors such as neuroblastoma impaired donor NK-cell-mediated cytotoxicity against neuroblastoma cells via blocking the NK cell receptor NKG2D. Interestingly, high doses of activated haploidentical NK-DLI could restore NKG2D-mediated cytotoxicity by scavenging of sMICA. 36 Pharmacological upregulation of NKG2D ligands is also being explored as a potential way of rendering blast cells more sensitive to NK cellmediated lysis. 37 Therefore, future studies should also focus on strategies to overcome these tumor immune escape mechanisms.
In conclusion, we could show for patients suffering from highrisk leukemia or tumors in a two-center phase II study, the feasibility of large-scale engineering of CD56 þ CD3 À NK cells and of their infusion very early (day þ 3) and early (day þ 40) post HSCT. Severe GVHD occurred, but was limited to the patients receiving the highest cumulative T-cell doses. Further studies are needed to determine the optimal dose and timing of NK cell immunotherapy for anti-leukemia activity, for activation and expansion of NK cells and for hastening immune recovery.
